Table 2.
Number of patientsa | % | ||
---|---|---|---|
2DL1 | + | 103 | 97 |
– | 3 | 3 | |
2DL2 | + | 52 | 49 |
– | 54 | 51 | |
2DL3 | + | 92 | 87 |
– | 14 | 13 | |
2DL5 | + | 51 | 48 |
– | 55 | 52 | |
2DS1 | + | 35 | 33 |
– | 71 | 67 | |
2DS2 | + | 50 | 48 |
– | 56 | 52 | |
2DS3 | + | 28 | 26 |
– | 78 | 74 | |
2DS4 | + | 102 | 96 |
– | 4 | 4 | |
2DS5 | + | 31 | 29 |
– | 75 | 71 | |
3DL1 | + | 103 | 97 |
– | 3 | 3 | |
3DS1 | + | 32 | 30 |
– | 74 | 70 | |
HLA-C | C1/C1 | 37 | 35 |
C1/C2 | 51 | 49 | |
C2/C2 | 17 | 16 | |
HLA-Bw4 | + | 74 | 70 |
– | 31 | 30 |
a One of the 107 patients was excluded from KIR analyses; two of the 107 patients were excluded from KIR–ligand analyses